StockData
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc. (AGIO) stock

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.68−0.21 (-0.70%)

Close on Nov 18, 2026Market cap $1.77BP/E –Yield –

Agios Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Agios Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $98.34M, up 140.6% year over year. For fiscal 2025 it was $54.03M, up 48.0% from the year before. Over ten years it grew -0.9% a year on average. The highest annual figure on record is $117.91M in fiscal 2019.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$54.03M+48.0%
FY2024Dec 31, 2024$36.50M+36.1%
FY2023Dec 31, 2023$26.82M+88.4%
FY2022Dec 31, 2022$14.24M–
FY2021Dec 31, 2021$0–
FY2020Dec 31, 2020$0-100.0%
FY2019Dec 31, 2019$117.91M+24.9%
FY2018Dec 31, 2018$94.39M+119.4%
FY2017Dec 31, 2017$43.01M-38.5%
FY2016Dec 31, 2016$69.89M+18.2%
FY2015Dec 31, 2015$59.12M-9.5%
FY2014Dec 31, 2014$65.36M+155.8%
FY2013Dec 31, 2013$25.55M+1.8%
FY2012Dec 31, 2012$25.11M+15.0%
FY2011Dec 31, 2011$21.84M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$44.75M+259.3%
Q1 FY2026Mar 31, 2026$20.75M+137.7%
Q4 FY2025Dec 31, 2025$19.97M+86.1%
Q3 FY2025Sep 30, 2025$12.88M+43.7%
Q2 FY2025Jun 30, 2025$12.46M+44.6%
Q1 FY2025Mar 31, 2025$8.73M+6.6%
Q4 FY2024Dec 31, 2024$10.73M+51.1%
Q3 FY2024Sep 30, 2024$8.96M+21.2%
Q2 FY2024Jun 30, 2024$8.62M+28.4%
Q1 FY2024Mar 31, 2024$8.19M+46.0%
Q4 FY2023Dec 31, 2023$7.10M+64.8%
Q3 FY2023Sep 30, 2023$7.40M+110.4%
Q2 FY2023Jun 30, 2023$6.71M+20.2%
Q1 FY2023Mar 31, 2023$5.61M+574.2%
Q4 FY2022Dec 31, 2022$4.31M–
Q3 FY2022Sep 30, 2022$3.52M–
Q2 FY2022Jun 30, 2022$5.58M–
Q1 FY2022Mar 31, 2022$832.00K–
Q4 FY2021Dec 31, 2021$0-100.0%
Q3 FY2021Sep 30, 2021$0-100.0%
Q2 FY2021Jun 30, 2021$0-100.0%
Q1 FY2021Mar 31, 2021$0-100.0%
Q4 FY2020Dec 31, 2020$44.05M+24.3%
Q3 FY2020Sep 30, 2020$34.71M+33.4%
Q2 FY2020Jun 30, 2020$37.35M+42.4%
Q1 FY2020Mar 31, 2020$87.10M+188.1%
Q4 FY2019Dec 31, 2019$35.44M+18.1%
Q3 FY2019Sep 30, 2019$26.02M+71.2%
Q2 FY2019Jun 30, 2019$26.22M-35.1%
Q1 FY2019Mar 31, 2019$30.23M+245.0%
Q4 FY2018Dec 31, 2018$30.01M+206.3%
Q3 FY2018Sep 30, 2018$15.20M+33.8%
Q2 FY2018Jun 30, 2018$40.41M+256.2%
Q1 FY2018Mar 31, 2018$8.76M-16.6%
Q4 FY2017Dec 31, 2017$9.80M-56.7%
Q3 FY2017Sep 30, 2017$11.36M+26.4%
Q2 FY2017Jun 30, 2017$11.35M–
Q1 FY2017Mar 31, 2017$10.51M–
Q4 FY2016Dec 31, 2016$22.65M–
Q3 FY2016Sep 30, 2016$8.99M–

More Agios Pharmaceuticals figures

See a number that looks wrong?